Robert Redd

9.5k total citations · 2 hit papers
102 papers, 2.7k citations indexed

About

Robert Redd is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Robert Redd has authored 102 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 37 papers in Pathology and Forensic Medicine and 30 papers in Hematology. Recurrent topics in Robert Redd's work include Lymphoma Diagnosis and Treatment (34 papers), Chronic Lymphocytic Leukemia Research (23 papers) and CAR-T cell therapy research (23 papers). Robert Redd is often cited by papers focused on Lymphoma Diagnosis and Treatment (34 papers), Chronic Lymphocytic Leukemia Research (23 papers) and CAR-T cell therapy research (23 papers). Robert Redd collaborates with scholars based in United States, Netherlands and Germany. Robert Redd's co-authors include Donna Neuberg, Scott J. Rodig, Margaret A. Shipp, Philippe Armand, Bjoern Chapuy, Azra H. Ligon, Gordon J. Freeman, Yasodha Natkunam, Sarah E. Daadi and Courtney Connelly and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Robert Redd

96 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

2016 555 citations Margaretha G.M. Roemer, Ranjana H. Advani et al. Journal of Clinical Oncology profile →
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

2017 473 citations R. Coleman Lindsley, Wael Saber et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Redd United States	23	1.5k	1.3k	888	678	636	102	2.7k
Stephen Opat Australia	25	980 0.7×	1.7k 1.4×	562 0.6×	570 0.8×	1.4k 2.2×	158	2.7k
Mathias Witzens‐Harig Germany	30	1.3k 0.8×	1.1k 0.9×	895 1.0×	665 1.0×	738 1.2×	136	2.8k
Amanda F. Cashen United States	29	1.0k 0.7×	1.4k 1.1×	445 0.5×	891 1.3×	549 0.9×	121	2.9k
Timothy S. Fenske United States	27	1.7k 1.1×	1.2k 1.0×	522 0.6×	543 0.8×	624 1.0×	162	2.6k
Eva Giné Spain	32	1.4k 0.9×	2.0k 1.6×	662 0.7×	461 0.7×	1.4k 2.2×	107	3.0k
María Gomes da Silva Portugal	20	1.1k 0.7×	1.1k 0.9×	714 0.8×	216 0.3×	436 0.7×	83	2.3k
Isabelle Bence‐Bruckler Canada	18	1.5k 1.0×	2.0k 1.6×	853 1.0×	459 0.7×	1.4k 2.1×	62	3.5k
Ellen D. Remstein United States	26	985 0.7×	1.5k 1.2×	571 0.6×	807 1.2×	973 1.5×	40	2.7k
Elena Hartmann Germany	26	992 0.7×	1.5k 1.2×	619 0.7×	276 0.4×	1.1k 1.8×	80	2.6k
Emma C. Scott United States	10	2.3k 1.5×	914 0.7×	1.3k 1.4×	311 0.5×	391 0.6×	27	3.2k

Countries citing papers authored by Robert Redd

Since Specialization

Citations

This map shows the geographic impact of Robert Redd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Redd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Redd more than expected).

Fields of papers citing papers by Robert Redd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Redd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Redd. The network helps show where Robert Redd may publish in the future.

Co-authorship network of co-authors of Robert Redd

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Redd. A scholar is included among the top collaborators of Robert Redd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Redd. Robert Redd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leblebjian, Houry, et al.. (2025). The impact of growth factor utilization on infection risk in patients receiving bispecific monoclonal antibodies. Journal of Oncology Pharmacy Practice. 3222431484–3222431484.

How, Joan, Orly Leiva, Robert Redd, et al.. (2025). Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes. PubMed. 2(3). 100051–100051. 2 indexed citations

Drobni, Zsófia D., Thiago Quinaglia, Hannah Gilman, et al.. (2025). Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy. JAMA Cardiology. 11(1). 68–68.

Nayak, Lakshmi, Ugonma Chukwueke, Christopher Meehan, et al.. (2024). A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).. Journal of Clinical Oncology. 42(16_suppl). 2006–2006. 9 indexed citations

Jacobsen, Eric D., Ashley Plant, Robert Redd, et al.. (2024). A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma. Leukemia & lymphoma. 65(12). 1864–1874. 1 indexed citations

Lee, David Jungpa, Habib El‐Khoury, Angela C. Tramontano, et al.. (2024). Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population. Blood Advances. 8(7). 1737–1746. 8 indexed citations

Redd, Robert, Martin J. Aryee, Anna E. Marneth, et al.. (2024). Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances. 8(23). 6043–6054. 3 indexed citations

Merryman, Reid W., Justin Rhoades, Kan Xiong, et al.. (2024). Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma. HemaSphere. 8(4). e47–e47. 1 indexed citations

Chapuy, Bjoern, Timothy R. Wood, Chip Stewart, et al.. (2024). DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma. Blood. 145(18). 2041–2055. 2 indexed citations

10.

Kelkar, Amar H., Edward R. Scheffer Cliff, Caron A. Jacobson, et al.. (2023). Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma. Annals of Internal Medicine. 176(12). 1625–1637. 18 indexed citations

11.

Mandato, Elisa, Qingsheng Yan, Jing Ouyang, et al.. (2023). MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8. Blood. 142(14). 1219–1232. 3 indexed citations

12.

Mandato, Elisa, Tianfang Ma, Vignesh Shanmugam, et al.. (2023). Cd70 Deficiency Impairs CD4 + and CD8 + T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas. Blood. 142(Supplement 1). 1624–1624. 1 indexed citations

13.

Ryan, Christine E., Rebecca L. Zon, Robert Redd, et al.. (2023). Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement. British Journal of Haematology. 203(5). 774–780. 8 indexed citations

14.

Rahman, Rifaquat, Steffen Ventz, Robert Redd, et al.. (2023). Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials. Clinical Cancer Research. 29(12). 2194–2198. 2 indexed citations

15.

Hacken, Elisa ten, Shanye Yin, Robert Redd, et al.. (2022). Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models. Blood Advances. 7(16). 4514–4517. 5 indexed citations

16.

Myllymäki, Mikko, Robert Redd, Christopher R. Reilly, et al.. (2020). Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 136(26). 3070–3081. 23 indexed citations

17.

Shen, Yu J., Yuji Mishima, Jiantao Shi, et al.. (2020). Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 137(17). 2360–2372. 32 indexed citations

18.

Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations

19.

Cader, Fathima Zumla, Ron C.J. Schackmann, Xihao Hu, et al.. (2018). Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment. Blood. 132(8). 825–836. 111 indexed citations

20.

Roemer, Margaretha G.M., Ranjana H. Advani, Robert Redd, et al.. (2016). Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research. 4(11). 910–916. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact